Merck & Company, Inc. (MRK) Earns “Buy” Rating from BMO Capital Markets
Merck & Company, Inc. (NYSE:MRK)‘s stock had its “buy” rating restated by BMO Capital Markets in a research report issued on Friday. They presently have a $72.00 price target on the stock. BMO Capital Markets’ price target would indicate a potential upside of 11.94% from the stock’s previous close.
A number of other analysts have also recently weighed in on the stock. Jefferies Group LLC restated a “sell” rating and issued a $52.00 price target on shares of Merck & in a report on Sunday, August 20th. J P Morgan Chase & Co raised their price target on shares of Merck & from $74.00 to $76.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. BidaskClub cut shares of Merck & from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. Vetr upgraded shares of Merck & from a “sell” rating to a “strong-buy” rating and set a $71.50 price target on the stock in a report on Monday, May 15th. Finally, Credit Suisse Group lowered their price target on shares of Merck & from $75.00 to $74.00 and set an “outperform” rating on the stock in a report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. Merck & presently has a consensus rating of “Hold” and a consensus target price of $69.68.
Shares of Merck & (NYSE MRK) traded down 0.241% on Friday, reaching $64.165. 2,867,994 shares of the company’s stock traded hands. The company has a market cap of $175.00 billion, a PE ratio of 34.740 and a beta of 0.81. Merck & has a 12-month low of $58.29 and a 12-month high of $66.80. The stock has a 50-day moving average price of $62.94 and a 200-day moving average price of $63.72.
Merck & (NYSE:MRK) last released its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. During the same period last year, the business earned $0.93 EPS. The company’s revenue was up .9% compared to the same quarter last year. Equities research analysts anticipate that Merck & will post $3.88 EPS for the current fiscal year.
Institutional investors and hedge funds have recently bought and sold shares of the business. Klingenstein Fields & Co. LLC raised its position in Merck & by 5.4% during the 1st quarter. Klingenstein Fields & Co. LLC now owns 446,450 shares of the company’s stock worth $28,368,000 after buying an additional 22,958 shares during the last quarter. First PREMIER Bank raised its position in Merck & by 2.7% during the 1st quarter. First PREMIER Bank now owns 21,475 shares of the company’s stock worth $1,364,000 after buying an additional 570 shares during the last quarter. Agran Libbie raised its position in Merck & by 83.0% during the 1st quarter. Agran Libbie now owns 11,918 shares of the company’s stock worth $757,000 after buying an additional 5,404 shares during the last quarter. Stevens Capital Management LP purchased a new position in Merck & during the 1st quarter worth approximately $15,126,000. Finally, Doyle Wealth Management purchased a new position in Merck & during the 1st quarter worth approximately $4,652,000. 73.02% of the stock is owned by institutional investors.
Merck & Company Profile
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.